We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Berkshire Hathaway, Exxon Mobil, Pfizer, Charles Schwab and ABB
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 20, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B - Free Report) , Exxon Mobil Corp. (XOM - Free Report) , Pfizer Inc. (PFE - Free Report) , The Charles Schwab Corp. (SCHW - Free Report) and ABB Ltd .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, ExxonMobil and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., Exxon Mobil Corp. and Pfizer Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Berkshire Hathaway have gained +3.6% over the past year against the Zacks Insurance - Property and Casualty industry's gain of +5.2%. The company is one of the largest property and casualty insurance companies measured by premium volume. Berkshire's inorganic growth story remains impressive with strategic acquisitions. A strong cash position supports earnings-accretive bolt-on buyouts and indicates the company's financial flexibility.
Continued insurance business growth fuels increase in float, drive earnings and generates maximum return on equity. The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditure remains a headwind for the company.
Exxon Mobil shares have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+77.0% vs. +46.8%). The company's bellwether status and an optimal integrated capital structure that has historically produced industry-leading returns make it a relatively lower-risk energy sector play. The company has made more than 30 discoveries in offshore Guyana since 2015.
ExxonMobil also has a strong presence in the prolific Permian Basin, where it expects to boost production volumes by 25% in 2022. The energy major has significantly lower debt exposure than composite players belonging to the industry. Also, XOM announced a fourth-quarter dividend of 91 cents per share, indicating an increase of 3.4% from the last paid dividend.
However, ExxonMobil has been constantly bearing the brunt of increasing expenses, adversely affecting the income. Also, the aggressive capital budget remains a headwind for the company. As such, the stock warrants a cautious stance.
Shares of Pfizer have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-15.8% vs. +13.6%). The company is facing currency headwinds and pricing pressure that are key top-line headwinds. Although no company is as strongly placed in the COVID vaccines/treatment market as Pfizer, concerns remain about its long-term growth drivers beyond its COVID-related products due to competitive pressure and the impact of the pandemic receding.
Nevertheless, Pfizer boasts a diversified portfolio of innovative drugs and vaccines, including Ibrance and Prevnar. Its COVID-19 vaccine has become a key contributor to the top line. The vaccine, together with its promising oral antiviral pill for COVID-19, Paxlovid, is expected to generate a combined $56 billion in sales in 2022. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
Other noteworthy reports we are featuring today include The Charles Schwab Corp. and ABB Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Berkshire Hathaway, Exxon Mobil, Pfizer, Charles Schwab and ABB
For Immediate Release
Chicago, IL – December 20, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B - Free Report) , Exxon Mobil Corp. (XOM - Free Report) , Pfizer Inc. (PFE - Free Report) , The Charles Schwab Corp. (SCHW - Free Report) and ABB Ltd .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Berkshire Hathaway, ExxonMobil and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., Exxon Mobil Corp. and Pfizer Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Berkshire Hathaway have gained +3.6% over the past year against the Zacks Insurance - Property and Casualty industry's gain of +5.2%. The company is one of the largest property and casualty insurance companies measured by premium volume. Berkshire's inorganic growth story remains impressive with strategic acquisitions. A strong cash position supports earnings-accretive bolt-on buyouts and indicates the company's financial flexibility.
Continued insurance business growth fuels increase in float, drive earnings and generates maximum return on equity. The non-insurance businesses are delivering improved results with increased revenues over the past few years. A sturdy capital level provides further impetus.
However, exposure to catastrophe loss induces earnings volatility and also affects the property and casualty underwriting results of Berkshire. Huge capital expenditure remains a headwind for the company.
(You can read the full research report on Berkshire Hathaway here >>>)
Exxon Mobil shares have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+77.0% vs. +46.8%). The company's bellwether status and an optimal integrated capital structure that has historically produced industry-leading returns make it a relatively lower-risk energy sector play. The company has made more than 30 discoveries in offshore Guyana since 2015.
ExxonMobil also has a strong presence in the prolific Permian Basin, where it expects to boost production volumes by 25% in 2022. The energy major has significantly lower debt exposure than composite players belonging to the industry. Also, XOM announced a fourth-quarter dividend of 91 cents per share, indicating an increase of 3.4% from the last paid dividend.
However, ExxonMobil has been constantly bearing the brunt of increasing expenses, adversely affecting the income. Also, the aggressive capital budget remains a headwind for the company. As such, the stock warrants a cautious stance.
(You can read the full research report on Exxon Mobil here >>>)
Shares of Pfizer have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-15.8% vs. +13.6%). The company is facing currency headwinds and pricing pressure that are key top-line headwinds. Although no company is as strongly placed in the COVID vaccines/treatment market as Pfizer, concerns remain about its long-term growth drivers beyond its COVID-related products due to competitive pressure and the impact of the pandemic receding.
Nevertheless, Pfizer boasts a diversified portfolio of innovative drugs and vaccines, including Ibrance and Prevnar. Its COVID-19 vaccine has become a key contributor to the top line. The vaccine, together with its promising oral antiviral pill for COVID-19, Paxlovid, is expected to generate a combined $56 billion in sales in 2022. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
(You can read the full research report on Pfizer here >>>)
Other noteworthy reports we are featuring today include The Charles Schwab Corp. and ABB Ltd.
Why Haven't You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.